Developing vaccines for the next pandemic will require an expanded portfolio that balances new and traditional technologies, together with increased capacity for vaccine production extending beyond multinational companies.
This article documents important examples of vaccine policies and diplomacy in Mexican history, some of them developed by new stakeholders as part of an emergent science diplomacy discourse.
